<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587988</url>
  </required_header>
  <id_info>
    <org_study_id>HM-TARO-301</org_study_id>
    <nct_id>NCT02587988</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate the Efficacy and Safety of HCP1302</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Phase Ⅲ Study to Evaluate the Efficacy and Safety of HCP1302 in Both Erectile Dysfunction and Hypertension Patients Being Treated With HGP0904</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to Evaluate the Efficacy and Safety of HCP1302
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-blind, Multicenter, Phase Ⅲ study to Evaluate the Efficacy and Safety of
      HCP1302 in Both Erectile Dysfunction and Hypertension Patients being Treated with HGP0904
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of IIEF-EF domain score</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of sitting diastolic blood pressure</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of sitting diastolic blood pressure</measure>
    <time_frame>baseline, 4weeks and 8weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of sitting systolic blood pressure</measure>
    <time_frame>baseline,4weeks, 8weeks and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of IIEF-EF domain score</measure>
    <time_frame>baseline, 4weeks and 8weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">232</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>HCP1302+HGP0904Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HCP1302+HGP0904Placebo for 12weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCP1302Placebo+HGP0904</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>HCP1302Placebo+HGP0904 for 12weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HCP1302</intervention_name>
    <arm_group_label>HCP1302+HGP0904Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HGP0904</intervention_name>
    <arm_group_label>HCP1302Placebo+HGP0904</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for HCP1302)</intervention_name>
    <arm_group_label>HCP1302Placebo+HGP0904</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for HGP0904)</intervention_name>
    <arm_group_label>HCP1302+HGP0904Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        At Visit1

          1. ≥19 age

          2. Hypertension Patients who need amlodipine 5mg

          3. Abnormal Erectile function ≥ at least 3months based on screening date

          4. Patients who are expected to frequent use of Tadalafil (at least two times for weeks)

          5. Patients understood the consents and purpose of this trial and signed informed consent
             form

        At Visit2

          1. 90≤ sitSBP &lt; 140 mmHg and 50 ≤ sitDBP &lt; 90 mmHg

          2. Sexual dysfunction rate ≥ 50% for 4 weeks run-in period

          3. International Index of Erectile Function(IIEF)- Erectile Function(EF) domain score ≤
             25

        Exclusion Criteria:

          1. History of hypersensitivity to Amlodipine or Tadalafil

          2. Has a severe liver disorder(Child-Pugh Class C) or liver enzyme (AST, ALT) level
             exceeds 3 times more than normal upper range

          3. Has a clinically significant renal failure (Scr &gt; 2mg/dl)

          4. Uncontrolled diabetes mellitus (HbA1C &gt;12%)

          5. At screening date, blood pressure gap of selected arms is sitSBP ≥20mmHg or sitDBP
             ≥10mmHg

          6. Taking PDE-5 inhibitors or other therapeutic agents for Erectile Dysfunction within 7
             days based on screening date

          7. No reaction to PDE-5 inhibitors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2015</study_first_submitted>
  <study_first_submitted_qc>October 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Erectile dysfunction &amp; Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

